David E. Gerber
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers 61
- Lung Cancer Research Studies 43
- Colorectal Cancer Treatments and Studies 22
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 114
- Lung Cancer Diagnosis and Treatment 57
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 31
- Immunology top 2%
- Phagocytosis and Immune Regulation 19
- Internal Medicine top 2%
-
- Ethics in Clinical Research 30
David E. Gerber
277 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 5.4k
- Pulmonary and Respiratory Medicine 4.4k
- Cancer Research 1.1k
- Immunology 1.2k
- Internal Medicine 183
Countries citing papers authored by David E. Gerber
This map shows the geographic impact of David E. Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gerber more than expected).
Fields of papers citing papers by David E. Gerber
This network shows the impact of papers produced by David E. Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gerber. The network helps show where David E. Gerber may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David E. Gerber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 30 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 14 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 3 | |
| 10 | 2022 | 12 | |
| 11 | 2021 | 20 | |
| 12 | 2021 | 12 | |
| 13 | 2020 | 8 | |
| 14 | 2020 | 6 | |
| 15 | 2019 | 33 | |
| 16 | 2019 | 19 | |
| 17 | 2017 | 13 | |
| 18 | 2013 | 86 | |
| 19 | 2012 | 35 | |
| 20 | Targeted therapies: a new generation of cancer treatments. | 2008 | 319 |
About David E. Gerber
David E. Gerber is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 292 papers that have together received 9.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (114 papers), Cancer Immunotherapy and Biomarkers (61 papers), Lung Cancer Diagnosis and Treatment (57 papers), Lung Cancer Research Studies (43 papers), Cancer Genomics and Diagnostics (31 papers), Ethics in Clinical Research (30 papers), Colorectal Cancer Treatments and Studies (22 papers) and Phagocytosis and Immune Regulation (19 papers). The work is most often cited by research in Oncology (5.4k citations), Pulmonary and Respiratory Medicine (4.4k citations) and Cancer Research (1.1k citations). David E. Gerber has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Lorraine Pelosof, Yang Xie, Joan H. Schiller, John D. Minna, Julie R. Brahmer, Sandi L. Pruitt, Scott Gettinger, Laura Q.M. Chow, Shaheen Khan and Jonathan W. Goldman. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.